Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Net Margin (2019 - 2025)

BridgeBio Pharma's Net Margin history spans 7 years, with the latest figure at 125.09% for Q4 2025.

  • For Q4 2025, Net Margin rose 438103.0% year-over-year to 125.09%; the TTM value through Dec 2025 reached 144.39%, up 9705.0%, while the annual FY2025 figure was 144.39%, 9705.0% up from the prior year.
  • Net Margin for Q4 2025 was 125.09% at BridgeBio Pharma, up from 151.4% in the prior quarter.
  • Across five years, Net Margin topped out at 17732.17% in Q4 2021 and bottomed at 40632.84% in Q3 2022.
  • The 5-year median for Net Margin is 4416.33% (2023), against an average of 6531.85%.
  • The largest YoY upside for Net Margin was 11607725bps in 2021 against a maximum downside of -3758901bps in 2021.
  • A 5-year view of Net Margin shows it stood at 17732.17% in 2021, then plummeted by -141bps to 7357.81% in 2022, then crashed by -31bps to 9635.99% in 2023, then surged by 53bps to 4506.12% in 2024, then surged by 97bps to 125.09% in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Net Margin are 125.09% (Q4 2025), 151.4% (Q3 2025), and 164.52% (Q2 2025).